According to a Biospace report, EpiCept has filed AmiKet™ (amitriptyline 4%, ketamine 2% cream) for Fast Track designation with the U.S. Food and Drug Administration (FDA).

AmiKet™ is a prescription topical cream under late stage clinical development by EpiCept for the treatment of chemotherapy-induced peripheral neuropathic pain.